Integrated clinical chemistry and immunoassay analyzer market to hit $7.59 billion by 2030

The integrated clinical chemistry and immunoassay analyzer market is projected to grow from $5.99 billion in 2025 to $7.59 billion by 2030, driven by demand for faster, more automated diagnostic testing. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Integrated analyzers combine clinical chemistry and immunoassay testing on one automated platform, helping labs cut manual steps and shorten turnaround times. - The market outlook signals continued investment in higher-throughput diagnostics as healthcare systems face more chronic disease testing and faster decision support needs.

What happened: - The integrated clinical chemistry and immunoassay analyzer market is expected to rise from $5.99 billion in 2025 to $6.27 billion in 2026. - The market is projected to reach $7.59 billion by 2030. - The forecast implies a 4.7% CAGR from 2025 to 2026 and a 4.9% CAGR through 2030. - The Business Research Company released the market outlook July 2, 2026. - The report covers regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the market report. - View the full market report.

The details: - The market’s earlier growth was tied to manual sample handling, fragmented diagnostic workflows, longer result turnaround times, limited automation in immunoassay and chemistry testing, and reliance on separate analyzers for different assays. - Growth through 2030 is expected to be supported by demand for high-throughput diagnostic systems, expansion of automated lab infrastructure, wider use of multiplex integrated analyzers, advances in precision diagnostics, and stronger needs for rapid clinical decision support. - Key trends include fully automated diagnostic workflows, consolidation of multiplex testing on single platforms, better reagent usage, cloud-based laboratory data management systems, and more point-of-care integrated diagnostic technologies. - Integrated clinical chemistry and immunoassay analyzers can measure multiple biochemical markers at once on a single platform. - These systems support high-volume testing, improve diagnostic efficiency, and reduce manual intervention. - Chronic disease prevalence is a major demand driver because aging populations are increasing the need for routine testing, biomarker identification, and ongoing monitoring. - The World Health Organization said in February 2024 that new cancer cases could exceed 35 million by 2050, up 77% from 20 million in 2022. - North America held the largest market share in 2025. - Asia-Pacific is forecast to grow the fastest over the coming years.

Between the lines: - The forecast suggests laboratories are moving toward more consolidated testing platforms to manage volume, labor pressure and speed requirements. - Chronic disease growth and cancer screening needs are likely to keep diagnostic automation near the center of hospital and lab purchasing decisions. - The geographic split points to a mature North American market and stronger expansion opportunity in Asia-Pacific.

What's next: - The market is expected to keep expanding as labs adopt more automated and integrated systems. - Future growth will likely depend on how quickly providers upgrade infrastructure, adopt multiplex testing and add cloud-connected lab tools. - Demand from routine chronic disease monitoring and precision diagnostics is expected to remain a key tailwind.

The bottom line: - Integrated clinical chemistry and immunoassay analyzers are moving from efficiency tools to core diagnostic infrastructure as labs seek faster, more automated testing at scale.